MedTrace Logo

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

NCT06927635 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2025-09-05

No results posted yet for this study

Summary

This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).

Conditions

  • Castrate Resistance Prostate Cancer
  • OligoProgressive Metastatic Disease

Interventions

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

SBRT will be delivered as per institutional standard.

OTHER

Systemic therapy

Participants will receive Systemic Therapy. Participants in Arm 1 - SOC may change the Systemic Therapy throughout treatment. Participants in Arm 2 - Experimental will remain on the same Systemic Therapy throughout treatment.

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Rachel Glicksman, MD · Princess Margaret Cancer Centre - University Health Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-08
Primary Completion
2030-06-30
Completion
2030-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06927635 on ClinicalTrials.gov